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Advances in large-scale analysis of human genomic variability provide unprecedented opportunities to study the
genetic basis of susceptibility to infectious agents. We report here the use of an in vitro system for the identification of a
locus on HSA8q24.3 associated with cellular susceptibility to HIV-1. This locus was mapped through quantitative linkage
analysis using cell lines from multigeneration families, validated in vitro, and followed up by two independent
association studies in HIV-positive individuals. Single nucleotide polymorphism rs2572886, which is associated with
cellular susceptibility to HIV-1 in lymphoblastoid B cells and in primary T cells, was also associated with accelerated
disease progression in one of two cohorts of HIV-1–infected patients. Biological analysis suggests a role of the rs2572886
region in the regulation of the LY6 family of glycosyl-phosphatidyl-inositol (GPI)–anchored proteins. Genetic analysis of
in vitro cellular phenotypes provides an attractive approach for the discovery of susceptibility loci to infectious agents.
Citation: Loeuillet C, Deutsch S, Ciuffi A, Robyr D, Taffe´ P, et al. (2008) In vitro whole-genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol 6(2): e32. doi:10.
1371/journal.pbio.0060032
Introduction
Some individuals do not become infected to the HIV-1
virus despite repeated exposures, and among those that do,
there is marked variation in the clinical course and
progression to AIDS [1]. Although a number of host genetic
determinants of susceptibility to HIV-1 have been identiﬁed
through the analysis of candidate genes—most notably CCR5
D32 and HLA alleles—only a fraction of the observed
phenotypic variation can be explained by variation at these
loci [2,3]. Thus, there is a considerable interest in applying
unbiased methods such as whole-genome analysis for the
identiﬁcation of novel susceptibility loci to human pathogens
[1]. This hunt is, however, plagued by numerous confounding
factors such as the lack of ascertainment of informative
patient cohorts and difﬁculties to control for the variability
of the infectious agent. Whole-genome mapping for viral
susceptibility has been reported in mice for the murine
adenovirus type 1 [4], and in mosquitoes for the dengue-2
virus [5]. Recently, the ﬁrst genomewide association analysis
for determinants of host control of HIV-1 in humans has
been completed [6].
Whole-genome scans can also be performed through the
analysis of family data using linkage analysis, an approach
widely used to map monogenic disorders [7,8]. The need for
family-based data has limited the use of this approach in the
HIV-1 ﬁeld because of the rarity, beyond instances of vertical
transmission, of multi-case family infections. Studies of host
genetic susceptibility to HIV-1 are also confounded by
differences in virulence of the infecting viral strain [1].
To circumvent these limitations, we established an in vitro
system to address the genetic control of cellular susceptibility
to HIV-1 using cell lines from multi-generation families
[9,10]. We used families from the Centre d’Etude du
Polymorphisme Humain (CEPH) resource (up to four grand-
parents and an average of eight children per family),
consisting of Epstein-Barr virus (EBV)–immortalized lympho-
blastoid B cell lines (LCL). CEPH LCLs have been extensively
genotyped, and the data are publicly available (http://snpdata.
cshl.edu/population_studies/linkage_maps//). CEPH LCLs
were previously used to identify genomic loci inﬂuencing
sodium–lithium counter transport [11], natural variation in
gene expression [12–15], transcriptional response to ionizing
radiation [16], susceptibility to chemotherapy [17], and the
relative impact of nucleotide and copy number variation on
gene expression [18,19]. We hypothesized that CEPH LCLs
could allow genome-wide investigation of interindividual
variation of cellular susceptibility to infection with an
isogenic virus, under standardized conditions and a con-
trolled environment.
Results/Discussion
We designed the study to progress through consecutive
steps including: (i) the identiﬁcation by linkage and associ-
ation of candidate markers associated with in vitro cellular
susceptibility to an HIV-1-based vector, (ii) in vivo validation
of candidate polymorphisms in humans infected with HIV,
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(iii) investigation of potential biological mechanisms (Figure
1).
Since B cells are not a natural target of HIV-1, we
established the conditions for efﬁcient transduction of
lymphoblasts with a VSV.G (vesicular stomatitis virus G
protein)-pseudotyped HIV-1–based vector (HIV.GFP). We
ﬁrst assessed to what extent immortalized B cells reﬂect the
behavior of CD4þT cells by transducing puriﬁed CD4þT cells
and EBV-immortalized B cells, from the same 11 Caucasian
healthy blood donors, with the same HIV.GFP. We used the
green ﬂuorescent protein (GFP) transgene expression as a
reporter for permissiveness to lentiviral infection. We
observed a signiﬁcant correlation (Pearson r2 ¼ 0.56, p ¼
0.007) between the level of transduction of CD4þT cells and B
lymphoblastoid cells for the same individuals (Figure S1).
Thus, we hypothesized that transduction of B cells can
capture a signiﬁcant proportion of interindividual variation
of post-entry events in the HIV-1 life cycle (reverse tran-
scription, integration, transcription, and translation). Addi-
tional validation of the assay established the intra- and
interday reproducibility of the transduction phenotype in
CEPH LCLs, and ruled out an inﬂuence of potential
confounders such as EBV copies per cell and the level of
expression of the EBV-transforming protein LMP1 (unpub-
lished data).
To determine whether variation in cellular susceptibility to
the HIV.GFP virus has a genetic component we estimated
heritability (h2, i.e., the proportion of variance attributable to
additive genetic factors) in ﬁve CEPH pedigrees (76 individ-
uals). In parallel, we also scored eight additional traits
unrelated to HIV susceptibility (EBV copy number, EBV
LMP1 oncogene CD11a, CD19, CD21, CD23, CD39, CD54).
We observed a signiﬁcant heritability of the HIV suscepti-
bility trait (h2¼ 0.54, p¼ 1.63106), as well as for most of the
other traits, with h2 values in the same range as those
reported for gene expression variation traits [20] (Figure S2).
In view of these signiﬁcant heritability results, we extended
the analyses to 15 CEPH pedigrees (198 individuals) for the
lentiviral cellular permissiveness trait (Figure S2), and we
selected the expression of the endogenous cell surface marker
CD39 (EBV receptor), and of the EBV-encoded LMP1 protein
as additional study phenotypes.
To identify genomic loci that contribute to the variation in
cellular permissiveness to HIV.GFP, we performed a quanti-
tative genome-wide linkage analysis using a panel of 2,600
SNP markers with an effective resolution of 3.9 cM.
Calculations were performed using the variance components
analysis option from Merlin [21]. A region on HSA8q24
(marker rs1398296) showed the highest multipoint linkage
score (logarithm of the odds [LOD] ¼ 2.89, p ¼ 1.3 3 1004;
Figure 2A). To determine the signiﬁcance of this ﬁnding, we
performed 500 simulations in which genotypes were random-
ized but the phenotype was kept constant, so as to preserve
the heritability of the trait, the marker density, and the
missing data patterns [22]. The distribution of maximum
LOD scores of the simulations revealed that the observed
HIV.GFP linkage peak is signiﬁcant on a genome-wide basis at
the 95% signiﬁcance level (Figure 2A).
In order to independently conﬁrm and ﬁne-map the
linkage analysis result, we assayed LCLs from 56 unrelated
CEPH individuals that have been genotyped at a high density
in the frame of the HapMap project [23]. The association
analysis was performed using 521 tag SNPs in a 3-Mb region
centered on the initial linkage assignment. A single SNP,
rs2572886G.A, was strongly associated with HIV.GFP per-
missiveness (p ¼ 1.8 3 105), and statistical signiﬁcance was
maintained after Bonferroni correction for multiple testing
and permutation analysis (n¼ 10,000) (Figure 2B). Allele A of
marker rs2572886 is associated with an average 1.4-fold
increase in susceptibility to the HIV.GFP in LCLs from
unrelated individuals, p ¼ 0.001 (Figure 2C). Similar steps
were taken for the secondary study phenotypes unrelated to
lentiviral cellular susceptibility, which led to the precise
identiﬁcation (by linkage and followed by association) of a
region involved in cis-regulation of CD39 expression (Figure
S2). In contrast, no locus was identiﬁed affecting LMP1
expression, suggesting a more complex control of this trait by
multiple genes.
Because observations were all made on B cells, we next
assessed the potential role of rs2572886 as a susceptibility
factor for HIV-1 infection in CD4þ T cells. We genotyped the
Figure 1. Study Flowchart
LCL, lymphoblastoid B cell lines; HIV.GFP, vesicular stomatitis virus G
protein-pseudotyped HIV-1-based vector; CEPH, Centre d’Etude du
Polymorphisme Humain; SNP, single nucleotide polymorphism.
doi:10.1371/journal.pbio.0060032.g001
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Author Summary
Individuals differ in their susceptibility to the HIV-1 virus, and the
determinants of susceptibility are encoded in the human genome.
Genetic variants influencing this trait have been identified by
investigating candidate genes thought likely to be involved in HIV-1
pathogenesis or by whole-genome association studies, which type
more than 500,000 genetic variants per individual (genome-wide
association studies) to see which ones associate with susceptibility.
We have addressed the issue of identification of new genetic
variants influencing susceptibility to HIV-1 by a novel strategy based
on the in vitro infection of cells. For this, immortalized B
lymphocytes from 15 families (198 cell lines) were infected by a
HIV-based vector. Differences in cellular susceptibility to infection—
a genetic trait—could be mapped to a precise region on
Chromosome 8, suggesting a role of the LY6 family of GPI-anchored
proteins in HIV-1 infection. Genetic analysis of in vitro standardized
cellular phenotypes provides a new approach to the discovery of the
basis of genetic susceptibility to infectious agents.
SNP in a collection of puriﬁed CD4þ T cells obtained from
128 Caucasian healthy blood donors. CD4þ T cells were
infected with a replicating HIV-1, and permissiveness was
assessed by p24 antigen production [3]. A signiﬁcant
association was again obtained for SNP rs2572886 and cellular
susceptibility to HIV-1 on this independent sample (p¼0.019)
using a biological system that more closely resembles the in
vivo situation. Consistent with the results of transduction of B
cells with a HIV-1–based vector, in CD4þ T cells, the allele A
of marker rs2572886 is associated with a 1.6-fold increase in
susceptibility to infectious HIV-1 virus than CD4þ T cells of
noncarriers, as assessed in a 7-d replication kinetics analysis
(Figure 2D). The size effect associated with rs2572886 in vitro
is comparable to that identiﬁed for other genetic variants
inﬂuencing the HIV life cycle [3].
Since the previous results were obtained from in vitro
assays, we set out to assess the potential association of
rs2572886 with disease progression in HIV-1 infected
individuals. The rs2572886 SNP has a minor allele frequency
of 7% in Caucasians (Utah CEPH individuals), 19% in West
Africans (Yoruba Hapmap sample), and 23% in Asians (Han
Chinese and Japanese, HapMap sample). We genotyped 805
individuals recruited in the frame of the genetic project of
the Swiss HIV Cohort Study (http://www.shcs.ch) who pro-
vided informed consent. These patients contributed consec-
utive CD4þ T cell data (n¼ 4,999 measurements) and viremia
(n¼1,926 measurements) over an average follow-up period of
7 y in the absence of anti-retroviral drug treatment. The
rs2572886A allele was associated with greater viral load, and
faster progression of immunosuppression, as deﬁned by the
Figure 2. Genome Scan and Fine Mapping of an HIV-1 Susceptibility Locus, and In Vitro Validation of the Candidate SNP Marker
(A) Linkage analysis with 15 families and 2,600 markers identifies a quantitative trait locus (QTL) on HSA8q24.3. The highest multipoint LOD score of
2.89, p¼ 1.33 1004 (marker rs1398296) was significant at genome-wide level as determined by permutation analysis (95% significance threshold of
2.83, dotted line).
(B) Association analysis in 56 unrelated individuals, using 521 SNPs from the HapMap project centered 3 Mb around the initial QTL, identifies marker
rs2572886 (p¼ 1.83 105). The association remained significant after correction for multiple testing by Bonferroni (dashed line) or permutation analysis
(dotted line).
(C) The candidate marker is associated with a significant 1.4-fold increase in susceptibility to the HIV.GFP.
(D) rs2572886A is associated with a significant 1.6-fold increase in susceptibility of CD4þ T cells from healthy blood donors to replicating HIV-1,
differences between the alleles remain significant (p¼ 0.0331) after removing the outliers.
doi:10.1371/journal.pbio.0060032.g002
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slope of CD4þ T cells depletion over time (Figure 3A and 3B).
Individuals homozygous for the minor allele variant (n ¼ 7)
exhibited, as a group, a faster disease progression, but no
conclusions can be made with such a small sample size. The
same trends were also present in the incident cohort of 259
individuals identiﬁed within a 1-y interval of seroconversion
(Figure 3C and 3D), although the limited numbers precluded
signiﬁcant association. These results are consistent with the
in vitro data, since the A allele, which was associated with
higher susceptibility of infection in the cellular systems, was
associated with greater viral load and faster progression in
vivo.
As an additional validation step, we genotyped a second
independent cohort including 189 individuals with a precise
date of seroconversion (Figure 3E and 3F), which was
collected in the context of a whole-genome association
analysis [6]. No association was detected in this cohort;
however, the power to detect association in a sample of this
size is estimated to be around 25%. These patients were
recruited by eight different cohorts, while the original results
were established using Swiss HIV cohort data. When pooling
the discovery incident subcohort and the validation cohort,
the association of rs2572886 on both the CD4 and viral load
did not reach signiﬁcance despite the increased number of
samples to 448. However, the combined sample is far from
homogeneous. Thus this association should be considered as
suggestive at this point..
The association results should be discussed in the frame of
the recently published genome-wide association analysis of
host determinants of viral setpoint [6]. First, the marker
identiﬁed in the current study, rs2572886, is neither present
nor tagged by the Illumina HumanHap550 BeadChip used in
Figure 3. Assessment of rs2572886A in an HIV-1–Infected Human Cohort in the Absence of Therapy
(A) Pattern of viral load in the full study population; each gray point represents a single viral load determination; the red (rs2572886A heterozygous),
black line (individuals with the common allele), and orange lines (minor allele variant homozygous) represent the trend trajectories.
(B) Pattern of CD4þ T cell depletion in the full study population; each gray point represents a single CD4þ T cell determination.
(C) Pattern of viral load in infected individuals with known date of infection (incident sub-cohort).
(D) Pattern of CD4þ T cell depletion in the incident sub-cohort.
(E) Pattern of viral load in the validation incident cohort.
(F) Pattern of CD4þ T cell depletion in the validation incident cohort.
doi:10.1371/journal.pbio.0060032.g003
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the paper by Fellay et al. [6]. In addition, the design and
premises of the genome-wide association and those of the
genome scan reported herein are different: (i) the manuscript
by Fellay et al. led to the identiﬁcation of acquired/innate
immunity loci (in major histocompatibility complex [MHC])
that cannot be captured in a cellular assay that investigates
the viral life cycle; (ii) the study design in the paper by Fellay
was powered to detect only very strong and sufﬁciently
common genetic determinants; (iii) the standardized infec-
tion conditions and the study endpoint (expression of a
reporter) that were used in the current study are very
different from the conditions encountered in a population of
HIV-infected individuals. It is through the nature of these
profound study design differences that we aimed at generat-
ing complementary information to that provided by the
genome-wide association analyses.
To provide a reference parameter that would allow
comparison with genetic variants identiﬁed in other studies,
we estimated the proportion of variation explained by
rs2572886 and compared it to the contribution of CCR5
D32 in the same study population. Including CCR5 D32 into
the model increased the proportion of variation explained by
1.9% for the CD4 cell count and 0.4% for the viral load. For
rs2572886A, the estimates were 0.8% and 1%, respectively.
For comparison, age at infection contributed to an increase
in the proportion of variation explained of 1.4% for the CD4
cell count and 0.05% for the viral load, whereas the increase
was 3% and 3.1%, respectively, for gender. These values are
comparable to estimates indicated in the literature for
various genetic variants inﬂuencing HIV pathogenesis [24],
although direct comparisons are difﬁcult due to different
study designs. In contrast, the proportion of variation
explained by rs2572886 or CCR5 D32 is considerable smaller
than that for the genetic determinants reported in the study
by Fellay et al., reﬂecting the fact that this genome-wide
association study was powered to detect strong genetic
effects. Thus, HCP5 and HLA-C variants explained 9.6% and
6.5% of the total variation in viral load, respectively, and an
SNP near the RNF39 and ZNRD1 genes explained 5.8% of the
total variation in disease progression [6].
The rs2572886 SNP is located in a nonconserved intergenic
region on the telomeric end of Chromosome 8q (Figure S4). It
is ﬂanked on both sides by genes of the LY6/uPAR family
(Figure S3). The LY6 genes are characterized by conserved
cysteine-rich domains with speciﬁc disulﬁde bonding pat-
terns but with little homology (20%–30% amino acid
conservation among family members); members are either
glycosyl-phosphatidyl-inositol (GPI)–anchored cell-surface
receptors or secreted cytotoxins. Eight genes are located at
8q24.3: LY6K, SLURP1, LYPD2, LYNX1, LY6D, GML, LY6E,
and LY6H. The functions of the encoded proteins are diverse
but not well understood [25]. None has been associated with
HIV-1 in the past, although the LY6H gene was reported to be
up-regulated upon HIV infection [26]. A related protein of
the LY6/uPAR family, the urokinase-type plasminogen acti-
vator receptor, coded by a gene in Chromosome 19, has been
reported up-regulated in HIV-infected individuals, and
proposed to participate in the innate immunity to HIV-1
through an interferon (IFN)-like mechanism [27,28].
The SNP rs2572886 is located in a recombination hot spot
between two linkage disequilibrium blocks. We resequenced
the surrounding region (; 13 kb) in 30 chromosomes to
identify additional SNPs in linkage disequilibrium with
rs2572886 that might point toward a biological function.
Although two closely positioned SNPs—rs12546765 and
rs12546801—were associated with rs2572886 in this limited
resequencing dataset, they are not found in linkage disequi-
librium in HapMap (pairwise r2 ¼ 0.03). The region (;1 kb)
where rs2572886 is located is only present once in the human
genome. We downloaded the homologous region of chim-
panzee and Rhesus macaque and sequenced it in seven
additional primates (bonobo, gorilla, orang-utan, nomascus
gibbon, siamang gibbon, baboon, and African green monkey).
rs2572886G.A was particularly variable among primates,
with ‘‘G’’ representing the ancestral nucleotide in Old World
monkeys, ‘‘A’’ the ancestral residue in hominoids, and ‘‘T’’ in
gibbons.
To identify candidate genes that could be functionally
related to the rs2572886 SNP, we performed quantitative 3C
(chromatin conformation capture) [29], with the goal of
detecting potential chromatin interactions between the SNP
region and neighboring genes. We tested 11 regions by
Taqman real-time PCR, spanning a distance of 190 kb
surrounding the SNP. We focused primarily on the upstream
areas (promoters) of genes in the locus. Results from cross-
linked cells were compared to randomly ligated BAC DNA
from the same region to correct for interassay differences
and potential ligation biases. As expected, we observed a high
level of enrichment with a region located 3.1 kb from the SNP
(positive control) due to random chromatin interactions that
have been reported to occur between regions separated by
less than 5 kb [30]. The trend for enrichment rapidly
decreased with increasing distance. Interestingly, we detected
higher than background peaks of enrichment on the up-
stream areas of two genes—LY6D and LYPD2 (Figure 4)—
suggesting that these are good candidates for functional
interaction with the associated SNP. There are no apparent
interactions between the SNP and the nearby GML promoter,
despite its relative proximity (12 kb) in comparison to the
LY6D (35 kb) and LYPD2 (70 kb) genes.
We prioritized the following proteins for additional
biological assessment: LY6D and LYPD2 on the basis of
chromatin conformation capture analysis, SLURP1 based on
its unique status of secreted protein, and GML because of the
proximity to the genetic marker. First, we overexpressed each
of the four proteins from several vector backgrounds in 293T
and HeLa cells to assess whether this would inﬂuence
transduction by HIV.GFP. No signiﬁcant changes in cellular
infectivity were detected upon overexpression in these cell
lines (Table S1).
In general, all eight genes of the LY6/uPAR family show
detectable, but very low levels of expression as assessed by
quantitative RT-PCR (unpublished); this precludes gene
expression variation analysis to determine whether the
genotype at rs2572886 correlates with expression levels of
nearby genes. LY6D and LYPD2, which showed relatively
higher expression levels, were silenced in HeLa cells by small
interfering RNA (siRNA). Silencing with three different
siRNA was successful for LY6D and suboptimal for LY6PD2.
After transduction with HIV.GFP, we observed minor
modiﬁcations in rates of cellular infection (Table S1). These
ﬁndings are interesting, but given the cell type used and the
harsh treatment of the cells, they are not conclusive enough
to make a functional link for these genes. Overall, the
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biological basis for a role the LY6/uPAR family of proteins in
HIV-1 cellular susceptibility remains elusive after this ﬁrst
line of biological screening. Additional analyses will be
required to convincingly demonstrate a role for these
proteins in the HIV life cycle.
In summary, by using a multi-step procedure involving a
whole-genome linkage scan followed by association studies,
we identiﬁed a locus on HSA8q24 that inﬂuences cellular
susceptibility to HIV-1, and possibly progression of HIV-1
infection in vivo. Although the initial ﬁndings were based on
transduction of transformed B lymphoblastoid cells with a
HIV-1–based vector, subsequent experiments ﬁrst on primary
CD4þ T cells infected with replicating HIV, and second on a
cohort of untreated HIV patients, supported the initial
observations of association. In addition, although quantita-
tive 3C data suggest a possible participation of genes of the
LY6/uPAR family, further work is required to decipher the
biological mechanism underlying this association.
Materials and Methods
Plasmids. Members of the LY6/uPAR family—LY6D (GenBank
NM_003695), LYPD2 (NM_205545), GML (NM_002066, SC303114;
OriGene), Lynx1c (NM_177457), Slurp1 (NM_020427), and Slurp2
(NM_177458)—were ampliﬁed by RT-PCR from RNA extracted from
human cell lines (HeLa or 293T), and cloned into pCI-neo. LY6D and
LYPD2 were tagged C-terminally with an HA tag.
Cell culture. 293T cells were cultivated in Dulbecco’s modiﬁed
Eagle Medium (DMEM; Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 50 lg/ml gentamycin. 293T
cells (33106 cells) were cotransfected with 20 lg total of DNA (empty
pCI vectorþ increasing amounts of pCI vector containing the gene of
interest) using the calcium phosphate technique. Twelve hours post-
transfection, cells were washed and 300,000 cells were seeded in six-
well plates and incubated further for 36 h to allow the expression of
the gene of interest before HIV-based vector infection.
CEPH cell lines. EBV-transformed B cell lines were obtained from
the CEPH collection through the Coriell Institute for Medical
Research (http://locus.umdnj.edu/nigms/ceph/ceph.html). Cells were
cultivated in RPMI 1640/Glutamax-I medium (Invitrogen) supple-
mented with 15% fetal calf serum (FCS, Inotech). They were
maintained by replacing half medium twice a week. Pedigrees studied
were numbers 102, 884, 1328, 1331, 1332, 1333, 1334, 1340, 1341,
1345, 1346, 1347, 1362, 1408, and 13292.
CD4þ T cell isolation and B cell immortalization. Cells from 11
white healthy blood donors were used to isolate CD4þT cells by using
anti-CD4 magnetic beads (Miltenyi Biotech). Cells were cultured in
RPMI1640/Glutamax-I medium supplemented with 20% FCS, 20 U/ml
human interleukin-2 (IL-2, Roche) and 50 lg/ml gentamicin (Invi-
trogen) following stimulation with phytohemagglutinin (PHA) at 2
mg/ml for 2 d [31]. The CD4-negative cell fraction was exposed to
EBV containing supernatant from a B95–8 cell line according to
current protocols [32].
HIV-based vector production. To produce HIV-based vector
particles (HIV.GFP), 293T cells (3 3 106 cells) were cotransfected
with four plasmids using the calcium phosphate method. Plasmids
encoded the VSV-G pantropic envelope (pMD.G), the Gag and Pol
proteins (pCMVDR8.92), Rev (pRSV-Rev), and the fourth plasmid
encoded the HIV vector segment carrying GFP as the reporter
transgene under the control of the CMV promoter (pWPTS-GFP)
(kind gifts from D.Trono, EPFL, Lausanne, Switzerland; see http://rd.
plos.org/pbio.0060032.1 for vector details). Forty-eight hours after
transfection, the supernatant was collected, centrifuged to pellet
cellular debris and ﬁltered through 0.45-lm ﬁlters. Viral particles
were concentrated by centrifugation through a 100-kDa cut-off
membrane (Centricon Plus-70; Millipore AG).
HIV-based vector transduction (single-round infectivity assay).
Transduction of CEPH cells and of the B cells of healthy blood donors
(0.53104 cells in 96 wells) was performed by spinoculation with HIV-
based particles for 3 h at 1500g and 22 8C. After 72 h, cells were
harvested and expression of GFP protein was monitored by
ﬂuorescence activated cell sorting (FACS) analysis with mock
transduced cells as control. This was performed twice in triplicate
at 1-wk intervals. Similarly, transfected 293T cells (in six-well plates)
were infected with HIV-based particles (25 ng p24 equivalent) in the
presence of 10 lg/ml DEAE-dextran in 1 ml D-10 for 5 h. Culture
medium was replaced and cells were incubated for 24 h before FACS
analysis of GFP expression. Typically, 20%–30% of GFPþ cells were
obtained for controls.
HIV infection. Healthy blood donors’ CD4þ T cells (106 cells) were
infected with NL4-3BaL virus (1,000 pg of p24 antigen) in a 1-ml ﬁnal
Figure 4. Long-Range Interactions between rs2572886 and LY6/uPAR Gene Promoters
Curves show results of quantitative chromatin conformation capture (3C) for four independent CD4þ cell lines. The y-axis corresponds to interaction
enrichment relative to background (furthest point) and corrected according randomly ligated BAC. The x-axis shows relative distance to rs2572886.
doi:10.1371/journal.pbio.0060032.g004
PLoS Biology | www.plosbiology.org February 2008 | Volume 6 | Issue 2 | e320324
HIV-1 Susceptibility Locus
volume for 2 h at 37 8C in 5% CO2. Cells were washed and cultured
for 7 d. Virus-containing supernatant was harvested, and p24 antigen
production was monitored by an enzyme-linked immunosorbent
assay (ELISA) (Abbott).
Phenotyping. For cell surface molecule staining, 105 CEPH cells
were washed, resuspended in PBS/0.5% BSA (Sigma) and incubated
with primary monoclonal antibodies (mAbs) or isotypes for 15 min at
room temperature (RT). Primary mAbs were : anti-CD11a (Dako,
MHM24), -CD19 (Dako, HD37), -CD21 (Dako, 1F8), -CD23 (Dako,
MHM6), -CD39 (Serotec, A1), -CD54 (Dako, 6.5B5), and the negative
control was mouse IgG1FITC (Dako, X0927). All mAbs were used at 1/
50, except CD19 used at 1/20. For intracellular staining, CEPH cells
were washed and resuspended in cytoﬁx/cytoperm solution (Becton
Dickinson) for 20 min at 4 8C. After two washes with permwash, cells
were resuspended in permwash with primary anti-LMP1 (1/50, S12, a
gift from S. Rothenberger) or negative control antibody mouse IgG2a
(1/50, Dako), for 15 min, at RT. After washes, cells were incubated in
permwash with secondary anti-mouse PE (1/30, Dako). After wash,
cells were ﬁxed (CellFix, Becton Dickinson) and analyzed using a
FACSCalibur system for 10,000 events. Positive events were deﬁned as
a ﬂuorescence level superior to that of isotypic control. Determi-
nation of EBV copy number was carried out by real-time PCR by
using speciﬁc probes as described [33].
Heritability, linkage, simulations, and associations studies. Herit-
ability calculations (h2) were performed using the ‘‘polygenicscreen’’
command from the SOLAR software [34]. SNP genotyping data,
consisting of 2,688 autosomal SNPs were downloaded from the SNP
Consortium database (http://snpdata.cshl.edu/population_studies/
linkage_maps/) [35]. Multipoint linkage with the SNP map was
performed using Merlin [36] with the –VC option, after Mendelian
inconsistencies (PEDCHECK) [37] and unlikely genotypes (PEDWIPE)
[38] were removed. To calculate the empirical signiﬁcance of the
linkage results, we performed 500 simulations for each quantitative
trait using the –simulate command from Merlin with different seed
numbers. We extracted the highest result from each simulation to
build signiﬁcance distributions. All simulations were performed using
a cluster of 32 HP/Intel Itanium 2 based servers at the Vital-IT Center
(http://www.vital-it.ch/). Association analysis of quantitative pheno-
types (% of GFP-positive cells and / mean ﬂuorescence intensity (MFI)
of CD39), and corrections for multiple testing were performed using
the PLINK software (http://pngu.mgh.harvard.edu/;purcell/plink/
anal.shtml). Genotypes were downloaded from the HapMap project
URL (http://www.hapmap.org/cgi-perl/gbrowse/gbrowse/hapmap/),
HapMap public release number 19.
Cohort analysis. Data from both incident (patients identiﬁed during
primary infection or who have had a negative and positive test for HIV
infection within a narrow time interval, 1 y in this study, in which case
the date of infection is estimated as the mid-point), as well as data from
prevalent cases (i.e., individuals already HIV-seropositive by the time
they entered the study, unknown date of infection) were analysed
longitudinally by modeling the CD4 T cell count and HIV-1 RNA
marker’s trajectories over time for the different genotype groups. The
analysis was conducted using population-averaged marginal modeling
[39], because the focus of the study was to investigate the effect of
speciﬁc genetic factors on disease progression at the population level.
In a marginal model, the mean regression function is modeled
independently from the variance–covariances matrix. We used frac-
tional polynomials to assess the best-ﬁtting functional form. The viral
load (log scale) and the CD4 (square root scale) trajectories post
seroconversion were linear and appeared stationary. Therefore, linear
functions of time, along with interactions with polymorphisms and
covariables (age at infection and gender) were considered. The impact
of genotype on slope and intercept was assessed using Wald test, and
the proportion of explained variation was assessed [40]. A multivariate
distribution was ﬁtted to the data by score-like methods (generalized
estimating equations) [41]. The correlation structure was assumed to
be well represented by an autoregressive process of order 1. To limit
the impact of frailty selection, only the data for the ﬁrst eight years
since seroconversion were considered. The analysis was repeated
considering, in turn, only the incident, prevalent, and both cohorts.
Subanalyses were also performed considering the Caucasian group
only. For the prevalent cases, an estimate of the unknown date of
infection was obtained using the markers data and deﬁning for each
patient an infection window based on his or her last negative and ﬁrst
positive available HIV tests. The date of infection was then imputed
using a methodology that extends published methods [42,43] to
accommodate multiple marker measurements per individual (P. Taffe
and M. May, unpulished data, and [44]. A second incident cohort,
recruiting individuals from various European countries, was used to
validate results obtained from the analysis of the incident cohort
recruited within the Swiss HIV Cohort study. Statistical analyses were
conducted using SAS version 9.1 for Windows, as well as STATA 9.2 .
Re-sequencing in human and nonhuman primates. The region (;1
kb) around the candidate marker was resequenced by using forward
primer SG2000 (59-AGTTCATACCCCTTTGCCAGGTTG) and re-
verse primer SG2001 (59-GAAGCCTTACCTGCTTCCTGCC), and
forward primer SG1829 (59-TTCCCTGAGCTTGCAGGACTC) and
reverse primer SG1853 (59-CTCTACACACCTACCTTGCTGGGA) to
generate overlapping PCR products.
Sequences have been submitted to GeneBank for bonobo
(EU340888, Pan paniscus), gorilla (EU340889, Gorilla gorilla), bornean
orang-utan (EU340890 , Pongo pygmaeus), nomascus (EU340891,
Hylobates leucogenys), siamang (EU340892, Hylobates syndactylus), baboon
(EU340893 Papio hamadryas), and African green monkey (EU340894,
Cercopithecus [chlorocebus] aethiops).
Quantitative chromatin conformation capture. Approximately 107
stimulated expanded primary CD4þ T cells [31] were crosslinked in
their media for 10 min at RT with 1% formaldehyde (v/v). Crosslinking
was quenched with 125 mM glycine prior to two successive washes with
1xPBS. Pelleted cells were resuspended into 5-ml ice-cold lysis buffer
(10mM Tris HCl, pH 8.0, 10 mM NaCl, 0.2% (v/v) NP-40) comple-
mented with protease inhibitors (Complete, Roche) and 0.5 mM PMSF.
Lysis of the cells was allowed to proceed for 10 min on ice with mild
shaking. Nuclei were recovered by centrifugation (600g for 5 min at 4
8C) and resuspended into 500-ll 1.2xDpnII restriction buffer (NEB).
Nuclei were lysed with 0.3% (v/v) SDS for 60 min at 37 8C. SDS was
sequestered with 2% (v/v) Triton X-100 for another 60 min at 37 8C.
Chromatin was subsequently restricted overnight at 37 8C with 500 U
DpnII (NEB) in a ﬁnal reaction volume of 600 ll. After heat
inactivation of the restriction enzyme (10 min at 65 8C), chromatin
was dialyzed (Slide-A-Lyzer, Pierce) for 1 h against 1.5 l of water at RT
and transferred into 7 ml ligation reaction mix (50 mM Tris HCl, pH
8.0, 10 mM MgCl2, 0.5mg/ml BSA, 10mM b-mercapto-ethanol, 0.5 mM
ATP and 400 U T4 DNA ligase (NEB). The ligation reaction was
performed for 4 h at 16 8C followed by another 30 min at RT.
Crosslinking was heat-reversed and proteins were degraded (300 lg
proteinase K) overnight at 65 8C in a hybridization oven. DNA was
puriﬁed by phenol/chloroform/isoamyl alcohol [25:24:1(v/v)] extraction,
precipitated with isopropanol, and washed with ethanol 70%. DNA was
subsequently resuspended with 200 ll 1xTE pH 8.0 and treated with 50
lg RNaseA for 30 min at 37 8C. Finally, DNA was extracted with 1
volume phenol/chloroform/isoamyl alcohol [25:24:1(v/v)], ethanol pre-
cipitated, and resuspended into 100 ll 1xTE pH 8.0. Cross-linking was
independently performed on four CD4þ lines derived from different
individuals, two of whom (2 and 4) were heterozygous for rs2572886.
For quantitative Taqman PCR, we designed 11 assays comprising
the PCR primers and a dual-labeled probe sitting at the predicted
DpnII junction between the target and bait regions (primer and
probe sequences are available upon request). Reactions were set up
using a Biomek 2000 robot (Beckman), in a 10-ll volume in 384-well
plates. Three replicates per assay per sample were performed. PCRs
were run in an ABI 7900 Sequence Detection System (Applied
Biosystems) with the following conditions: 50 8C for 2 min, 95 8C for
10min, and 50 cycles of 95 8C 15 s/60 8C for 1 min. Each reaction
contained 300 nM of each primer and 250 nM of probe.
For the 3C samples, approximately 200 ng of DNA was used per
well, and for the BAC (digested – randomly ligated) samples, 10 ng of
DNA was used. Normalization for each assay was performed using the
values obtained from BAC experiment (all assays are expected to give
the same result, given that the naked BAC was fully digested and re-
ligated, and all ligation combinations are expected to be present
equimolarly). Enrichment was calculated with respect to the most
centromeric probes, which showed very low levels of interaction.
Note in Press: Recently, Brass et al [45] identiﬁed through a siRNA
screen over 250 HIV-dependency factors. Among these there were
three members of the LY6/uPAR family (GML, LY6D, and LYPD4).
This new evidence provides independent support for a biological role
of the LY6/uPAR family in HIV-1 pathogenesis.
Supporting Information
Figure S1. Validation of the CEPH Model to Study HIV-1
Susceptibility
CD4þ T cells and B cells from same healthy blood donors were
transduced with the HIV.GFP. Linear regression of one representa-
tive experiment for the percentage of GFP-positive cells is shown.
Each point represents the mean of triplicate values.
Found at doi:10.1371/journal.pbio.0060032.sg001 (41 KB PPT).
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Figure S2. Expression and Heritability of HIV-1 Susceptibility Trait
in CEPH Families
(A) Heritability estimate (h2) for eight study traits (percent of positive
cells and mean ﬂuorescence intensity, MFI), and for the EBV copy
number (** p , 0.001, *** p , 0.0001).
(B) Representation of interindividual (black dots), and interfamily
(red bar¼median value for each family) differences in percentage of
GFP-positive cells after transduction with a HIV.GFP of 198
lymphoblastoid B cell lines from 15 CEPH pedigrees.
Found at doi:10.1371/journal.pbio.0060032.sg002 (68 KB PPT).
Figure S3. Genome Scan and Fine Mapping of CD39 Expression (MFI
Trait)
(A) Results of linkage analysis with 15 families. A single locus on
HSA10q23 (rs766083) is signiﬁcant after correction by permutation
analysis (n ¼ 500).
(B) Results of association analysis in 56 independent individuals using
SNPs from the HapMap project. All SNPs in a 700 kb region
surrounding the CD39 gene were used. rs numbers next to peaks
indicate signiﬁcant SNPs after correction for multiple testing.
Found at doi:10.1371/journal.pbio.0060032.sg003 (94 KB PPT).
Figure S4. Chromosomal Localization of rs2572886
The SNP is localized in an intergenic region containing genes
belonging to the LY6/uPAR family. The ﬁgure shows images generated
through the University of California at Santa Cruz genome browser
and Haploview software.
Found at doi:10.1371/journal.pbio.0060032.sg004 (168 KB PPT).
Table S1. Infectivity of HIV.GFP of Cells Transfected with or
Silenced for the Gene of Interest from the LY6/uPAR Family
Values reﬂect relative infectivity to that of the mock control. None of
the differences are statistically signiﬁcant.
Found at doi:10.1371/journal.pbio.0060032.st001 (26 KB DOC).
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